Thread regarding CVSHealth (CVS)

II'm just going to leave this here:
• CVS Health (NYSE:CVS) perks up 3% premarket after first quarter results for three months ended March 31, 2021 surpasses estimates.
• Q1 Total Revenues increased 3.5% Y/Y to $69.1B. Analyst expectations were $68.35B.
• Pharmacy Revenues rose 3.8% for Q1 compared to the prior year primarily driven by net new business, growth in specialty pharmacy, product mix and brand inflation.
• Retail/LTC Sales advanced 2.3% Y/Y primarily driven by increased COVID-19 diagnostic testing and vaccinations and brand inflation, partially offset by lower front store revenues.
• Non-GAAP EPS grew 6.8% over prior year to $2.04, beating forecast of $1.72. Non-GAAP net income rose to $2.7B compared to $2.5B in Q1 2020.
• GAAP EPS rose 9.8% to $1.68. Net income increased to $2.2B vs. $2B in prior year.
• Q1 cash flows from operating activities of $2.9B compared to $3.3B in Q1 02020.
• Medical membership as of March 31, of 23.6M increased 214,000 members compared with December 31, 2020, primarily reflecting increases in Medicare and Medicaid products, partially offset by a decline in Commercial products.
• The Company raised its FY 2021 non-GAAP EPS guidance to $7.56 to $7.68 from $7.39 to $7.55 (consensus $7.53).
• GAAP EPS was also upped to $6.24 to $6.36 from $6.06 to $6.22; cash flow from operations guidance of $12.0B to $12.5B confirmed.